BioPharma Resources

Drug Trial Radar · NCT05917340

Intensified Short Course Regimen for TBM in Adults

Comparative Evaluation of Intensified Short Course Regimen and Standard Regimen for Adults TB Meningitis : an Open-label Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

372

Planned (sponsor's estimate)

Start

Mar 2024

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Indian Council of Medical ResearchGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
All India Institute of Medical Sciences, Jodhpur; Christian Medical College, Vellore, India; Jawaharlal Institute of Postgraduate Medical Education & Research; North Eastern Indira Gandhi Regional Institute of Health ans Medical Sciences; Madras Medical College; Rural Development Trust Hospital
First posted
Jun 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors. TBM poses one of the most difficult diagnostic and therapeutic challenges in modern clinical practice. High-quality robust clinical trials have made a considerable contribution to the treatment of pulmonary tuberculosis in the last four decades. However, evidence from such clinical trials is lacking in TBM and the treatment remains uncertain. There is a significant variation in the choice, dose and duration of drugs between countries, institutions and clinicians. Investigators propose a multi-centric open-label clinical trial to assess the efficacy of short-course anti-TB drugs with high dose rifampicin, and moxifloxacin along with conventional anti-TB drugs and adjuvant therapy with aspirin and corticosteroids. Controls will receive standard treatment as per national guidelines for TBM. The investigators also aim to assess the safety and tolerability of high-dose Rifampicin and Moxifloxacin and the Pharmacodynamics and Pharmacokinetics parameters of ATT (Rifampicin, INH, Moxifloxacin and Pyrazinamide) in CSF between the two groups

Conditions

  • Tuberculous Meningitis

Interventions

  • High dose rifampicin (25mg/kg)Drug

    Given for 2 months

  • Moxifloxacin 400mgDrug

    Given for 2 months

  • Aspirin 150 mgDrug

    Given for 2 months

  • IsoniazidDrug

    Given for 6 months

  • PyrazinamideDrug

    Given for 6 months

  • SteroidDrug

    Tapering dose of dexamethasone or prednisolone upto 8 weeks

  • RifampicinDrug

    Standard dose for 4 months after the initial treatment with high dose

  • HRZEDrug

    2 months

  • HREDrug

    7-10 months as per TB program guidelines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality rateTime frame: 12 months
  2. Disability rateTime frame: 12 months
  3. Mortality rateTime frame: 12 months
  4. Disability rateTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICMR- National Institute for Research in Tuberculosis

    Chennai, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.